8 results
Primary: To compare immunogenicity (humoral and cellular) induced by PCV10 and PCV13 after the booster dose of a complete vaccination series (3+1, the current NIP schedule) Secondary: To compare immunogenicity (humoral) induced by PCV10 and PCV13 at…
To assess the effect of alternative and reduced doses pneumococcal vaccination schedules using the 13-valent pneumococcal conjugate vaccine (PCV13, Wyeth) on the development of antibody titers directed against the different serotypes of pneumococci…
To evaluate the efficacy of JZP-110 administered once daily for up to 12 weeks in doses of 75, 150, and 300 mg compared to placebo in the treatment of excessive sleepiness in adult subjects with narcolepsy.
To evaluate the safety and tolerability of JZP-110 administered once daily for up to 52 weeks in doses of 75, 150, and 300 mg
Primary objective:- To evaluate the effect of JZP-110 on driving performanceSecondary objectives:- To evaluate the safety and tolerability of JZP-110- To explore SAFTE (Sleep, Activity, Fatigue, and Task Effectiveness) modeling using driving,…
To evaluate the efficacy of JZP-110 administered once daily for up to 12 weeks in doses of 37.5, 75, 150, and 300 mg compared to placebo in the treatment of excessive sleepiness in adult subjects with OSA.
Primary objective:- To evaluate the effect of JZP-110 on driving performanceSecondary objectives:- To evaluate the safety and tolerability of JZP-110- To explore SAFTE (Sleep, Activity, Fatigue, and Task Effectiveness) modeling using driving,…
Hypothesis: A booster dose of the naked (i.e. non-adjuvanted) 5x concentrated AKS-452X vaccine, will provide an enhanced immune response after vaccination with any of the registered vaccines, either as primary vaccin or booster vaccin, against COVID…